Fusion processing of itraconazole solid dispersions by kinetisol dispersing: a comparative study to hot melt extrusion.
KinetiSol Dispersing (KSD) is a novel high energy manufacturing process investigated here for the production of pharmaceutical solid dispersions. Solid dispersions of itraconazole (ITZ) and hypromellose were produced by KSD and compared to identical formulations produced by hot melt extrusion (HME). Materials were characterized for solid state properties by modulated differential scanning calorimetry and X-ray diffraction. Dissolution behavior was studied under supersaturated conditions. Oral bioavailability was determined using a Sprague-Dawley rat model. Results showed that KSD was able to produce amorphous solid dispersions in under 15 s while production by HME required over 300 s. Dispersions produced by KSD exhibited single phase solid state behavior indicated by a single glass transition temperature (T(g)) whereas compositions produced by HME exhibited two T(g)s. Increased dissolution rates for compositions manufactured by KSD were also observed compared to HME processed material. Near complete supersaturation was observed for solid dispersions produced by either manufacturing processes. Oral bioavailability from both processes showed enhanced AUC compared to crystalline ITZ. Based on the results presented from this study, KSD was shown to be a viable manufacturing process for the production of pharmaceutical solid dispersions, providing benefits over conventional techniques including: enhanced mixing for improved homogeneity and reduced processing times.
DiNunzio
James C
JC
Division of Pharmaceutics, The University of Texas at Austin, 1 University Station A1920, Austin, Texas 78712, USA. james.dinunzio@mail.utexas.edu
Brough
Chris
C
Miller
Dave A
DA
Williams
Robert O
RO
McGinity
James W
JW
D000284:Administration, Oral; D000818:Animals; D002626:Chemistry, Pharmaceutical / Q000379:methods; D004304:Dosage Forms; D004339:Drug Compounding / Q000379:methods*; D005079:Excipients; D065347:Hypromellose Derivatives; D017964:Itraconazole / Q000008:administration & dosage / Q000737:chemistry* / Q000493:pharmacokinetics; D008747:Methylcellulose / Q000031:analogs & derivatives / Q000737:chemistry / Q000493:pharmacokinetics; D051381:Rats; D017207:Rats, Sprague-Dawley; D012995:Solubility; D044366:Transition Temperature
D004304:Dosage Forms; D005079:Excipients; D017964:Itraconazole; D065347:Hypromellose Derivatives; D008747:Methylcellulose